NASDAQ: PROK PROKIDNEY CORP. 10-Q

ProKidney advances to late-stage trial, widens Q1 loss to $42.6M on pivotal study ramp-up

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade PROK commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.